排序方式: 共有7条查询结果,搜索用时 487 毫秒
1
1.
2.
3.
4.
Kallmann BA Sauer J Schliesser M Warmuth-Metz M Flachenecker P Becker Dagger G Rieckmann P Mäurer M 《Journal of neurology》2004,251(1):30-34
Abstract.Context: Brain atrophy is an indicator of diffuse brain pathology
that appears even in the early stages of multiple sclerosis
(MS). Magnetic resonance imaging (MRI) techniques used in
clinical trials suggest a correlation between ventricular
enlargement and axonal pathology and clinical disability in
MS.Objective: To evaluate by transcranial sonography (TCS) and MRI
ventricular diameters in order to assess prospectively the
development of brain atrophy in MS.Setting: MS outpatient clinic of a university hospital.Patients and
Methods: 38 MS patients (27 females, 11 males) were followed up for
2 years. Ventricular diameters (third ventricle, right and left
lateral ventricle) were determined by TCS at baseline, 12 and 24
months and correlated with clinical disability (Expanded
Disability Status Scale, EDSS), and the Multiple Sclerosis
Functional Composite Score (MSFC). MRI was performed at study
entry and after two years.Main outcome
measure: Correlation of ventricular diameters measured by TCS and
MRI with assessment of clinical disability in MS patients at
baseline and after two years.Results: TCS and MRI measurements especially of third ventricle
diameter matched closely at study entry and after two years (r =
0.9; p < 0.0001). At all time points the width of the third
ventricle was significantly correlated with clinical disability
(EDSS: r = 0.6, p < 0.01; MSFC: r = –0.6, p < 0.02). In
the follow-up over 2 years there was an increase of the width of
the third ventricle in comparison with study entry (p <
0.002). Increase of third ventricular width at study entry was
associated with higher EDSS levels after 2 years (p =
0.01).Conclusion: Assessment of ventricular diameters by TCS is a reliable
tool with which to monitor brain atrophy in the longitudinal
follow-up of MS patients. Because TCS is a simple, inexpensive,
non-invasive and generally available bedside-test it may be used
in clinical practice as well as in therapeutic trials to assess
brain atrophy.(died unexpectedly 05. 08. 2003) 相似文献
5.
Aurore Malric MD Anne‐Sophie Defachelles MD Thierry Leblanc MD PhD Brigitte Lescoeur MD Brigitte Lacour MD Michel Peuchmaur MD PhD Claude‐Alain Maurage MD PhD Gaëlle Pierron PhD Delphine Guillemot BcS Catherine Dubois d'Enghien Jean Soulier MD PhD Dominique Stoppa‐Lyonnet MD PhD Franck Bourdeaut MD PhD 《Pediatric blood & cancer》2015,62(3):463-470
6.
7.
1